Disclaimer:All content on this platform is sourced from the internet and is provided for informational purposes only. None of the content represents the views of this site, nor does it constitute investment advice. Please exercise caution when investing.

Faster global financial news!

BioNTech shares fell 1.2% in premarket trading after BMO downgraded the stock and cut its price target from $128 to $105, citing declining vaccine demand and the termination of a cancer vaccine trial.

08/09/2026 11:01 UTC
Share
Complaint Report
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
i
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.